ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2019
Apolipoprotein E particle size is increased in Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Multiomic Evidence for a Unified Model of Alzheimer's Disease Etiology Linking Microglial Flux Capacity and Astrocyte-Neuron Metabolic Breakdown.bioRxiv : the preprint server for biology · 2025Article
- Analysis of TEM micrographs with deep learning reveals APOE genotype-specific associations between HDL particle diameter and Alzheimer's dementia.Cell reports methods · 2025Article
- Review
- Microglial apolipoprotein E particles contribute to neuronal senescence and synaptotoxicity.iScience · 2024Article
- Ensemble Model for Diagnostic Classification of Alzheimer's Disease Based on Brain Anatomical Magnetic Resonance Imaging.Diagnostics (Basel, Switzerland) · 2022Article
- APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.Molecular neurodegeneration · 2022Review
- Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics.Frontiers in neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApolipoprotein E4 (apoE4) is the predominant risk factor for late-onset Alzheimer's disease (AD), but the question of which structural differences might explain its effect remains unclear.
methodsWe compared high-density lipoprotein-like apoE particles from 12 AD and 10 control patients using size-exclusion chromatography.
resultsApoE particles from patients genotyped as ε4/ε4 were 2.2 ± 0.3 times as massive as particles from ε3/ε3 control subjects and 1.4 ± 0.1 times as massive as particles from ε3/ε3 AD patients. The increased particle size was not because of incorporation of amyloid β or apoE proteolysis products. Particles from AD patients genotyped as ε3/ε3 were 1.59 ± 0.27 times as massive as ε3/ε3 control subjects. DISCUSSION: Increased particle size in AD is affected by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.